[1]
|
Clinical Evidence and Practice-Based Guidelines on the Utility of Basal
Insulin Combined Oral Therapy (Metformin and Glimepiride) in the
Current Era
Current Diabetes Reviews,
2023
DOI:10.2174/1573399819666230109104300
|
|
|
[2]
|
Benefits of the fixed‐ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time‐to‐control analysis of the LixiLan JP phase 3 trials
Diabetes, Obesity and Metabolism,
2020
DOI:10.1111/dom.14139
|
|
|
[3]
|
A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes
Diabetes Therapy,
2020
DOI:10.1007/s13300-020-00836-8
|
|
|
[4]
|
Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study)
Expert Opinion on Pharmacotherapy,
2020
DOI:10.1080/14656566.2020.1785430
|
|
|
[5]
|
Fixed‐ratio combination of basal insulin and glucagon‐like peptide‐1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge
Diabetes, Obesity and Metabolism,
2020
DOI:10.1111/dom.14095
|
|
|
[6]
|
Benefits of the fixed‐ratio combination of insulin glargine 100 units/
mL
and lixisenatide (
iGlarLixi
) in Japanese people with type 2 diabetes: A subgroup and time‐to‐control analysis of the
LixiLan JP
phase 3 trials
Diabetes, Obesity and Metabolism,
2020
DOI:10.1111/dom.14139
|
|
|
[7]
|
Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study
Current Medical Research and Opinion,
2020
DOI:10.1080/03007995.2020.1754182
|
|
|
[8]
|
Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
Diabetes Care,
2020
DOI:10.2337/dc19-2452
|
|
|
[9]
|
Fixed‐ratio combination of basal insulin and glucagon‐like peptide‐1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge
Diabetes, Obesity and Metabolism,
2020
DOI:10.1111/dom.14095
|
|
|
[10]
|
Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
Diabetes Therapy,
2019
DOI:10.1007/s13300-019-0613-7
|
|
|
[11]
|
Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan
Diabetology International,
2016
DOI:10.1007/s13340-015-0236-9
|
|
|
[12]
|
Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan
Diabetology International,
2016
DOI:10.1007/s13340-015-0250-y
|
|
|
[13]
|
Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study
Diabetes Therapy,
2015
DOI:10.1007/s13300-015-0111-5
|
|
|